A systematic review and meta-analysis of ten studies involving 1537 patients revealed that a common IL-6 pathway inhibitor used as therapy for immune diseases such as rheumatoid arthritis (tocilizumab) was associated with an increase in body weight as determined by BMI, pointing towards a role of IL-6 signaling in weight management [118]. Here, IL6 is linked to rheumatoid arthritis.